July 2018 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2017/18 Invitation to Tender, dated 2 November 2017.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (http://www.pgnz.org.nz/about-us-1/pharmacode(external link)) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (http://www.nzulm.org.nz/sponsors(external link)). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Fluticasone propionate |
Metered aqueous nasal spray, 50 mcg per dose, 120 dose pump bottle OP |
$2.18 |
$1.98 |
Flixonase Hayfever & Allergy |
1 September 2018 |
1 December 2018 |
|
Letrozole |
Tab 2.5 mg, 30 tablet blister pack |
$2.95 |
$4.68 |
Letrole |
1 September 2018 |
1 December 2018 |
|
Paracetamol |
Suppos 125 mg, 10 suppository blister pack |
$3.69 |
$3.29 |
Gacet |
1 September 2018 |
1 December 2018 |
|
Paracetamol |
Suppos 250 mg, 10 suppository blister pack |
$3.79 |
$3.79 |
Gacet |
1 September 2018 |
1 December 2018 |
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Date of reference pricing of other listed brands |
Sole Subsidised Supply date |
Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
|
Latanoprost |
Eye drops 0.005%, 2.5 ml dropper bottle, OP |
$1.50 |
$1.57 |
Teva |
1 February 2019 |
n/a |
1 July 2019 |
Hysite |
|
Paracetamol |
Suppos 500 mg, 50 suppository blister pack |
$12.60 |
$12.40 |
Gacet |
1 December 2018 |
1 February 2019 |
1 May 2019 |
Paracare |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Fluticasone propionate |
Metered aqueous nasal spray, 50 mcg per dose, 120 dose pump bottle |
$2.18 |
$1.98 |
Flixonase Hayfever & Allergy |
1% |
1 September 2018 |
1 November 2018 |
|
Letrozole |
Tab 2.5 mg, 30 tablet blister pack |
$2.95 |
$4.68 |
Letrole |
1% |
1 September 2018 |
1 November 2018 |
|
Oxaliplatin* |
Inj 5 mg per ml, 20 ml vial, 1 vial |
$16.00 |
$46.32 |
Oxaliccord |
1% |
1 November 2018 |
1 January 2019 |
|
Paracetamol |
Suppos 125 mg, 10 suppository blister pack |
$3.69 |
$3.29 |
Gacet |
1% |
1 September 2018 |
1 November 2018 |
|
Paracetamol |
Suppos 250 mg, 10 suppository blister pack |
$3.79 |
$3.79 |
Gacet |
1% |
1 September 2018 |
1 November 2018 |
|
* The price and subsidy of Oxaliccord inj 5 mg per ml, 20 ml vial in Section B of the Pharmaceutical Schedule will also be amended to the above price from 1 November 2018. The subisdy for oxaliplatin inj 1 mg for ECP (Baxter) in Section B of the Pharmaceutical Scheduel will change from $0.18 per 1 mg to $0.48 per 1 mg from 1 January 2019. |
|||||||
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Latanoprost |
Eye drops 0.005%, 2.5 ml dropper bottle |
$1.50 |
$1.57 |
Teva |
1% |
1 February 2019 |
1 April 2019 |
Hysite |
|
Paracetamol |
Suppos 500 mg, 50 suppository blister pack |
$12.60 |
$12.40 |
Gacet |
1% |
1 December 2018 |
1 February 2019 |
Paracare |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2016/17 Invitation to Tender, dated 3 November 2016, and
- the 2017/18 Invitation to Tender, dated 2 November 2017.
2016/17 Invitation to Tender
|
Chemical name |
Line item |
|
Adapalene |
Crm 0.1% |
|
Adapalene |
Gel 0.1% |
|
Beclomethasone dipropionate |
Metered aqueous nasal spray, 50 mcg per dose |
|
Beclomethasone dipropionate |
Metered aqueous nasal spray, 100 mcg per dose |
|
Brinzolamide |
Eye drops 1% |
|
Calcium folinate |
Inj 1 g |
|
Calcium folinate |
Inj 50 mg |
|
Calcium folinate |
Inj 100 mg |
|
Caspofungin |
Inj 50 mg |
|
Caspofungin |
Inj 70 mg |
|
Gemcitabine hydrochloride |
Inj 1 g |
|
Gemcitabine hydrochloride |
Inj 200 mg |
|
Lidocaine [lignocaine] hydrochloride |
Inj 1%, 5 ml |
|
Lidocaine [lignocaine] hydrochloride |
Inj 1%, 20 ml |
|
Lidocaine [lignocaine] hydrochloride |
Inj 2%, 5 ml |
|
Lidocaine [lignocaine] hydrochloride |
Inj 2%, 20 ml |
|
Lidocaine [lignocaine] hydrochloride |
Spray, 10 mg dose per spray |
|
Mercaptopurine |
Tab 50 mg |
|
Minocycline hydrochloride |
Tab 50 mg |
|
Minocycline hydrochloride |
Cap 100 mg |
|
Moxifloxacin |
Tab 400 mg |
|
Paraffin (Current access) |
White soft, 500 g |
|
Paraffin (Widened access) |
White soft, 500 g |
|
Tigecycline |
Inj 50 mg |
|
Zinc sulphate |
Cap 50 mg elemental |
2017/18 Invitation to Tender
|
Chemical name |
Line item |
|
Enalapril |
Tab 5 mg |
|
Enalapril |
Tab 10 mg |
|
Enalapril |
Tab 20 mg |
|
Heparin sodium |
Inj 1,000 iu per ml, 20-35 ml vial |
For products included in the 2016/17 and 2017/18 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.